Why Faeth Therapeutics, Inc. (FTH) stock fell 42.5% on Monday, November 9, 2026

Faeth Therapeutics, Inc. (FTH) closed at $12.68, down 42.49% on Monday, November 9, 2026, on volume of 4,045,534 shares (10.9× its 3-month average); market value about $300.0M.

What happened: primary sources

Events Nexqual found for FTH on Monday, November 9, 2026 or the trading day before (November 6, 2026):

• Nov 9, 2026: SEC 8-K: Other material event source
  Quoted from the filing: “On November 9, 2026, Faeth Therapeutics, Inc. (the "Company") made available a presentation to be used to discuss, among other things, the topline clinical data from the Company's Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.”
• Nov 9, 2026: SEC 8-K: Regulation FD disclosure source

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on FTH

FTH stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 9, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:24 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt